Corcept Therapeutics (CORT) Expected to Announce Quarterly Earnings on Monday

Corcept Therapeutics (NASDAQ:CORT) is projected to announce its Q1 2025 earnings results after the market closes on Monday, May 5th. Analysts expect Corcept Therapeutics to post earnings of $0.17 per share and revenue of $177.93 million for the quarter. Corcept Therapeutics has set its FY 2025 guidance at EPS.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $0.26 EPS for the quarter, missing the consensus estimate of $0.37 by ($0.11). Corcept Therapeutics had a net margin of 22.35% and a return on equity of 24.54%. The business had revenue of $181.89 million during the quarter, compared to the consensus estimate of $200.12 million. On average, analysts expect Corcept Therapeutics to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Corcept Therapeutics Stock Up 1.8 %

Shares of CORT opened at $72.77 on Friday. The firm has a fifty day moving average price of $65.70 and a 200-day moving average price of $60.08. The company has a current ratio of 3.70, a quick ratio of 3.64 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $7.72 billion, a P/E ratio of 57.75 and a beta of 0.22. Corcept Therapeutics has a 12-month low of $23.02 and a 12-month high of $117.33.

Insider Buying and Selling

In related news, insider Joseph Douglas Lyon sold 421 shares of the stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $60.58, for a total transaction of $25,504.18. Following the completion of the sale, the insider now owns 9,009 shares of the company’s stock, valued at $545,765.22. This represents a 4.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Sean Maduck sold 100,000 shares of Corcept Therapeutics stock in a transaction on Monday, March 31st. The stock was sold at an average price of $100.54, for a total transaction of $10,054,000.00. Following the completion of the transaction, the insider now directly owns 85,622 shares in the company, valued at $8,608,435.88. This represents a 53.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 163,124 shares of company stock worth $15,117,614 in the last three months. 20.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

CORT has been the topic of a number of research analyst reports. StockNews.com downgraded shares of Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, February 28th. Canaccord Genuity Group upped their target price on Corcept Therapeutics from $130.00 to $142.00 and gave the stock a “buy” rating in a report on Tuesday, April 1st. HC Wainwright raised their price target on Corcept Therapeutics from $115.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, March 31st. Truist Financial increased their target price on shares of Corcept Therapeutics from $76.00 to $150.00 and gave the stock a “buy” rating in a report on Monday, March 31st. Finally, Piper Sandler boosted their price target on shares of Corcept Therapeutics from $128.00 to $131.00 and gave the company an “overweight” rating in a report on Thursday, April 3rd. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $143.25.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.